Gallop Oncology's LYT-200 Shows Strong Efficacy with 13.2 Months Survival in AML
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Newsfilter
- Efficacy Breakthrough: LYT-200 demonstrated an initial median overall survival of 13.2 months in heavily pretreated patients when combined with standard care, significantly exceeding the expected survival of less than 2.5 months in acute myeloid leukemia (AML), indicating its potential in treatment.
- Favorable Safety Profile: In a trial involving 101 participants, LYT-200 showed no treatment-related serious adverse events, highlighting its good tolerability and supporting further development in AML patients.
- Broad Applicability: Responses were observed in patients with various high-risk mutations, suggesting LYT-200's potential applicability in AML and beyond, enhancing its market prospects.
- Clinical Trial Progress: Gallop Oncology plans to release final survival data in the first half of 2026 and engage with regulatory authorities regarding the registration pathway for LYT-200, demonstrating the company's confidence in the drug's future development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRTC
About PRTC
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Robert Lyne Appointed CEO of PureTech
- New CEO Appointment: PureTech Health has appointed Robert Lyne as the new chief executive officer.
- Announcement Date: The announcement regarding the appointment was made on Thursday.
Continue Reading
PureTech Appoints Robert Lyne as CEO, Focuses on Funding and Innovation
- Leadership Change: PureTech Health plc appoints Robert Lyne as CEO, aiming to leverage his extensive experience in the biotech sector to drive the company's strategic development in innovation and funding.
- Funding Plans: The company plans to secure funding for its newly founded entity, Celea Therapeutics, by the first half of 2026, which is expected to significantly reduce operational costs and enhance shareholder value.
- Capital Efficiency Improvement: Lyne emphasizes a streamlined operational structure and a disciplined investment strategy to ensure efficient capital utilization while advancing key innovation initiatives.
- Strategic Focus: The new CEO will concentrate on optimizing shareholder returns, with plans to evaluate potential capital return methods after Celea is fully financed, ensuring sustained growth in the biopharmaceutical sector.
Continue Reading